These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23690658)
21. Toll like receptor 9 antagonism modulates spinal cord neuronal function and survival: Direct versus astrocyte-mediated mechanisms. Acioglu C; Mirabelli E; Baykal AT; Ni L; Ratnayake A; Heary RF; Elkabes S Brain Behav Immun; 2016 Aug; 56():310-24. PubMed ID: 27044334 [TBL] [Abstract][Full Text] [Related]
22. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. Li Y; Cao H; Wang N; Xiang Y; Lu Y; Zhao K; Zheng J; Zhou H Vaccine; 2011 Mar; 29(11):2193-8. PubMed ID: 21036131 [TBL] [Abstract][Full Text] [Related]
23. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Li B; Zhang R; Li J; Zhang L; Ding G; Luo P; He S; Dong Y; Jiang W; Lu Y; Cao H; Zheng J; Zhou H Int Immunopharmacol; 2008 Mar; 8(3):379-89. PubMed ID: 18279792 [TBL] [Abstract][Full Text] [Related]
24. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412 [TBL] [Abstract][Full Text] [Related]
25. CpG DNA modulates interleukin 1beta-induced interleukin-8 expression in human bronchial epithelial (16HBE14o-) cells. Parilla NW; Hughes VS; Lierl KM; Wong HR; Page K Respir Res; 2006 Jun; 7(1):84. PubMed ID: 16740161 [TBL] [Abstract][Full Text] [Related]
27. Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice. Krogmann AO; Lüsebrink E; Steinmetz M; Asdonk T; Lahrmann C; Lütjohann D; Nickenig G; Zimmer S PLoS One; 2016; 11(1):e0146326. PubMed ID: 26751387 [TBL] [Abstract][Full Text] [Related]
28. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414 [TBL] [Abstract][Full Text] [Related]
29. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640 [TBL] [Abstract][Full Text] [Related]
30. CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis. Zhou DC; Su YH; Jiang FQ; Xia JB; Wu HY; Chang ZS; Peng WT; Song GH; Park KS; Kim SK; Cai DQ; Zheng L; Qi XF J Cell Physiol; 2018 May; 233(5):4245-4257. PubMed ID: 29057537 [TBL] [Abstract][Full Text] [Related]
31. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Hoque R; Sohail M; Malik A; Sarwar S; Luo Y; Shah A; Barrat F; Flavell R; Gorelick F; Husain S; Mehal W Gastroenterology; 2011 Jul; 141(1):358-69. PubMed ID: 21439959 [TBL] [Abstract][Full Text] [Related]
32. Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9. Ashman RF; Goeken JA; Lenert PS Int Immunopharmacol; 2011 Aug; 11(8):1032-7. PubMed ID: 21376154 [TBL] [Abstract][Full Text] [Related]
33. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Assaf A; Esteves H; Curnow SJ; Browning MJ Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862 [TBL] [Abstract][Full Text] [Related]
34. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. Xu H; An H; Yu Y; Zhang M; Qi R; Cao X J Biol Chem; 2003 Sep; 278(38):36334-40. PubMed ID: 12867418 [TBL] [Abstract][Full Text] [Related]
35. A toll-like receptor 9 antagonist reduces pain hypersensitivity and the inflammatory response in spinal cord injury. David BT; Ratnayake A; Amarante MA; Reddy NP; Dong W; Sampath S; Heary RF; Elkabes S Neurobiol Dis; 2013 Jun; 54():194-205. PubMed ID: 23313320 [TBL] [Abstract][Full Text] [Related]
36. TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to S. typhimurium. Trieu A; Bokil N; Dunn JA; Roberts TL; Xu D; Liew FY; Hume DA; Stacey KJ; Sweet MJ Immunol Cell Biol; 2009; 87(3):218-25. PubMed ID: 19048019 [TBL] [Abstract][Full Text] [Related]
37. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766 [TBL] [Abstract][Full Text] [Related]
38. Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. Rumio C; Sommariva M; Sfondrini L; Palazzo M; Morelli D; Viganò L; De Cecco L; Tagliabue E; Balsari A J Cell Physiol; 2012 Mar; 227(3):1107-13. PubMed ID: 21567398 [TBL] [Abstract][Full Text] [Related]
39. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982 [TBL] [Abstract][Full Text] [Related]
40. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. Sorrentino R; Morello S; Chen S; Bonavita E; Pinto A J Cell Physiol; 2010 Apr; 223(1):158-67. PubMed ID: 20049870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]